返回 
加入收藏
益气清肺汤联合化疗用于老年晚期非小细胞肺癌患者的疗效观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 益气清肺汤联合化疗用于老年晚期非小细胞肺癌患者的疗效观察 |
| TITLE： | |
| 摘要： | 目的：观察益气清肺汤联合化疗用于老年晚期非小细胞肺癌（NSCLC）患者的疗效。方法：将76例老年晚期NSCLC患者按随机数字表法分为对照组和观察组，各38例。两组患者入院后均给予水化、止吐及托烷思琼+地塞米松治疗，对照组患者第1、8天给予酒石酸长春瑞滨注射液25 mg/m2+0.9％氯化钠注射液125 ml，10 min内ivgtt；第1～3天给予顺铂注射液30 mg/m2+0.9％氯化钠注射液500 ml，3 h内ivgtt。观察组患者在对照组基础上加用益气清肺汤200 ml，每日1剂，分两次服用。两组均治疗2个月。观察两组患者临床疗效及治疗前后凝血状态、T细胞免疫功能、生存时间及生存质量。结果：观察组患者总有效率为63.1％，显著高于对照组的34.2％，差异有统计学意义（P＜0.05）。治疗前两组患者凝血状态及T细胞免疫功能比较，差异无统计学意义（P＞0.05）；治疗后，观察组患者纤维蛋白原（FIB）、D-二聚体（D-D）、CD8+水平显著降低，CD3+、CD4+、CD4+/CD8+水平显著升高，与治疗前及对照组比较，差异均有统计学意义（P＜0.05）。观察组患者中位生存时间为10.2个月，显著长于对照组的7.6个月，差异有统计学意义（P＜0.05）。治疗前，两组患者生存质量评分比较，差异无统计学意义（P＞0.05）；治疗后，观察组生存质量评分显著低于对照组，差异有统计学意义（P＜0.05）。结论：益气清肺汤联合化疗能明显改善老年晚期NSCLC患者凝血状态及免疫功能，延长其生存时间，提高其生存质量。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy of Yiqi qingfei decoction combined with chemotherapy in the treatment of elder advanced non-small cell lung cancer （NSCLC）. METHODS： 76 elder patients with NSCLC were randomly divided into control group and observation group， with 38 cases in each group. Both groups were given hydration， antiemetics and tropisetron+dexamethasone therapy. Control group was given Vinorelbine bitartrate injection 25 mg/m2+normal saline diluted to 125 ml， ivgtt within 10 min on the first and eighth day； given Cisplatin injection 30 mg/m2+normal saline 500 ml， ivgtt within 3 h. Observation group was addtionally given Yiqi qingfei decoction 200 ml one dose a day， at twice on the basis of control group. Both group were given 2 months of treatment. The clinical efficacy， and blood coagulation， T cell immune function， survival time and survive quality before and after treatment were observed in 2 groups. RESULTS： The total effective rate of observation group was 63.1％， which was significantly higher than that of control group （34.2％）， with statistical significance （P＜0.05）； there was no statistical significance in blood coagulation and T cell immune function of 2 groups before and after treatment（P＞0.05）； after treatment， fibrinogen （FIB）， D-dimer （D-D） and CD8+ levels of observation group were significantly reduced， while CD3+， CD4+ and CD4+/CD8+ were significantly increased， with statistical significance compared to before treatment and control group （P＜0.05）； median survival time of observation group was 10.2 month， which was significantly longer than that of control group （7.6 month）， with statistical significance （P＜0.05）； before treatment， there was no statistical significance in survival quality score between 2 groups （P＞0.05）； after treatment， the survive quality scores of observation group were significantly lower than that of control group， with statistical significance （P＜0.05）. CONCLUSIONS： For elder patients with NSCLC， Yiqi qingfei decoction combined with chemotherapy is help to improve the blood coagulation and immune function， extend the survival time， and improve the survive quality. |
| 期刊： | 2016年第27卷第11期 |
| 作者： | 王巧琳，邓皖利，陆明 |
| AUTHORS： | WANG Qiaolin，DENG Wanli，LU Ming |
| 关键字： | 益气清肺汤；化疗；晚期非小细胞肺癌；老年患者 |
| KEYWORDS： | Yiqi qingfei decoction； Chemotherapy； Advanced non-small cell lung cancer； Elderly patient |
| 阅读数： | 210 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
